Press Releases

 
Press Releases
  Date Title View
Jun 12, 2013
NEW HAVEN, Conn., June 12, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, President and Chief Executive Officer of Achillion, and members of the senior management team will present a corporate update and participate on a HCV Panel at the Wells Fargo 2013 Healthcare Conference on Tuesday...
PDF
May 30, 2013
— Advancement of ACH-3422 Complements Achillion's Portfolio of 2nd Generation Protease and NS5A Inhibitors Providing the Opportunity to Optimize Treatment Duration and Outcomes for All HCV Patients — — Conference Call and Webcast to be Hosted Today at 12:00pm EDT — NEW HAVEN, Conn., May 30, 2013 (GLOBE NEWSWIRE) -- Achi...
PDF
May 28, 2013
NEW HAVEN, Conn., May 28, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that President and Chief Executive Officer Michael D. Kishbauch has decided to retire. In conjunction with this decision, the Board has appointed President of Research and Development and Chief Scientific Officer, Milind Deshpande, Ph.D....
PDF
May 15, 2013
NEW HAVEN, Conn., May 15, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the appointment of David Apelian, M.D., Ph.D., MBA, to the position of Executive Vice President and Chief Medical Officer, effective May 28, 2013. Dr. Apelian wll assume responsibility for the clinical development of Achillion's portfoli...
PDF
May 9, 2013
NEW HAVEN, Conn., May 9, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at three upcoming investor conferences: Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013 at 3:00 p.m. PT at the Enco...
PDF
May 7, 2013
NEW HAVEN, Conn., May 7, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2013. For the first quarter of 2013, the Company reported a net loss of $11.7 million or $0.14 per share, compared with a net loss of $9.1 million or $0.13 per share for the first quar...
PDF
Apr 23, 2013
- Phase 1 Results Further Demonstrate Potency of ACH-3102 in Genotypes 1a and 1b and Against Resistant HCV-- Study Shows ACH-3102 and Sovaprevir Can be Co-Administered Without Interaction -- Total of Six Poster Presentations to be Made During EASL - AMSTERDAM, The Netherlands, April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (...
PDF
Apr 23, 2013
- ACH-3102 deemed safe and well-tolerated following 12 weeks of therapy - - High barrier to resistance demonstrated with no on-treatment virologic breakthrough observed - - Novel NS5A inhibitor study supports differentiated profile of ACH-3102 - NEW HAVEN, Conn., April 23, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) ...
PDF
Apr 16, 2013
NEW HAVEN, Conn., April 16, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C (HCV). The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sov...
PDF
Mar 1, 2013
NEW HAVEN, Conn., March 1, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that members of the senior management team will be presenting a company overview at two upcoming investor conferences: Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 2:50 p.m. ET at The Boston Marr...
PDF
FirstPrevious
...
7
...
NextLast
Achillion Pharmaceuticals